Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Pache

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
British Journal of Cancer|March 1, 1994
Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-upN Harbeck, M Untch, L Pache, et al.
Geburtshilfe Und Frauenheilkunde|February 1, 1993
[Importance of plasma PMN granulocyte elastase concentration determination in pregnant patients with premature rupture of fetal membranes]M Kolben, F Fischbach, H Hofmeister, et al.
Virology|November 21, 2008
Insights into adenovirus host cell interactions from structural studiesG R Nemerow, L Pache, V Reddy, et al.
Biological Chemistry Hoppe-Seyler|July 1, 1992
Tumor-associated urokinase-type plasminogen activator: biological and clinical significanceM Schmitt, F Jänicke, N Moniwa, et al.
Cancer Research|May 15, 1994
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1F Jänicke, L Pache, M Schmitt, et al.
Gynecologic Oncology|December 1, 1994
Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapyW Kuhn, L Pache, B Schmalfeldt, et al.
Breast Cancer Research and Treatment|January 1, 1993
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancerF Jänicke, M Schmitt, L Pache, et al.
Geburtshilfe Und Frauenheilkunde|February 1, 1996
-Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study-W Kuhn, B Schmalfeldt, J Dose, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1995
Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancerC Thomssen, M Schmitt, L Goretzki, et al.
Cancer|October 15, 1992
Radical surgical procedure improves survival time in patients with recurrent ovarian cancerF Jänicke, M Hölscher, W Kuhn, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
British Journal of Cancer|March 1, 1994
Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-upN Harbeck, M Untch, L Pache, et al.
Geburtshilfe Und Frauenheilkunde|February 1, 1993
[Importance of plasma PMN granulocyte elastase concentration determination in pregnant patients with premature rupture of fetal membranes]M Kolben, F Fischbach, H Hofmeister, et al.
Virology|November 21, 2008
Insights into adenovirus host cell interactions from structural studiesG R Nemerow, L Pache, V Reddy, et al.
Biological Chemistry Hoppe-Seyler|July 1, 1992
Tumor-associated urokinase-type plasminogen activator: biological and clinical significanceM Schmitt, F Jänicke, N Moniwa, et al.
Cancer Research|May 15, 1994
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1F Jänicke, L Pache, M Schmitt, et al.
Gynecologic Oncology|December 1, 1994
Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapyW Kuhn, L Pache, B Schmalfeldt, et al.
Breast Cancer Research and Treatment|January 1, 1993
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancerF Jänicke, M Schmitt, L Pache, et al.
Geburtshilfe Und Frauenheilkunde|February 1, 1996
-Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study-W Kuhn, B Schmalfeldt, J Dose, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1995
Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancerC Thomssen, M Schmitt, L Goretzki, et al.
Cancer|October 15, 1992
Radical surgical procedure improves survival time in patients with recurrent ovarian cancerF Jänicke, M Hölscher, W Kuhn, et al.
Pageof 2